AAD: Maintenance of Low Eczema Activity Seen After About 80 Days Off Tapinarof
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after treatment-free interval
AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
No new safety signals or reports of deaths, thromboembolic events, or major cardiovascular events reported
Considerable Proportion of Medical Device Adverse Events Reported Late
9.1 percent were reported after 180 days; small number of manufacturers submitted most of the late reports
Small Number of Acne Products Recalled for Problematic Levels of Benzene
Agency says 90 percent of tested products have undetectable or extremely low levels of benzene
Bronchodilator Responsiveness Positivity More Likely in Morning
Significant association seen for patients referred for asthma/query asthma, but not those referred for other reasons
No Weight Loss Benefit Seen for Neoadjuvant Semaglutide Before Weight Loss Surgery
No benefits seen in terms of weight loss, diabetes remission, surgery safety
AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications
Patients who continued Ozempic through total joint arthroplasty had the highest risk for complications
Remibrutinib Beneficial for Urticaria After H1-Antihistamine Treatment
Remibrutinib results in significant improvement in composite measure of itching and hives at week 12 after second-generation H1-antihistamine treatment
Free COVID-19 Test Program Stops Taking Orders
